Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Wary Of Future Competition In Renal Anemia Market

Executive Summary

The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.

Advertisement

Related Content

Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
GSK Kicks Off Two Large Outcomes Trials In A Competitive CKD Category
Japan Phase III Start Cements Roxadustat’s Lead
Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease
For GSK, Lots Of Drugs In R&D, But Many Are Long-Term

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel